Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Study did not meet key efficacy measures or internal hurdle rate for continued development Systemic
Study did not meet key efficacy measures or internal hurdle rate for continued development Systemic